image
Tandem Diabetes Care, Inc. TNDM
Healthcare - Medical - Devices - NASDAQ - US
Watchlist
$ 14.63
-3.84 %
$ 974 M
Market Cap
-5.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one TNDM stock under the worst case scenario is HIDDEN Compared to the current market price of 14.6 USD, Tandem Diabetes Care, Inc. is HIDDEN

TNDM Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one TNDM stock under the base case scenario is HIDDEN Compared to the current market price of 14.6 USD, Tandem Diabetes Care, Inc. is HIDDEN

TNDM Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one TNDM stock under the best case scenario is HIDDEN Compared to the current market price of 14.6 USD, Tandem Diabetes Care, Inc. is HIDDEN

TNDM Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart TNDM

image
1M -38%
6M -140%
1Y -178%
3Y -331%
5Y -586%
All
$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0$10.0$10.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
940 M REVENUE
25.74%
Growth Rates
1Year 25.74%
3Years 10.19%
5Years 21.01%
7Years 36.30%
10Years 34.17%
-99.1 M OPERATING INCOME
57.50%
Growth Rates
1Year 57.50%
3Years -130.55%
5Years -42.75%
7Years -6.70%
10Years -2.74%
-96 M NET INCOME
56.86%
Growth Rates
1Year 56.86%
3Years -92.82%
5Years -31.14%
7Years -3.99%
10Years -1.90%
24.2 M OPERATING CASH FLOW
176.16%
Growth Rates
1Year 176.16%
3Years -39.86%
5Years -10.38%
7Years 13.09%
10Years 9.13%
-23.5 M INVESTING CASH FLOW
72.61%
Growth Rates
1Year 72.61%
3Years 49.91%
5Years 16.24%
7Years -37.81%
10Years 4.04%
8.37 M FINANCING CASH FLOW
103.43%
Growth Rates
1Year 103.43%
3Years -45.59%
5Years -19.14%
7Years -17.58%
10Years 8.68%
234 M REVENUE
-17.06%
Growth Rates
1Year 25.74%
3Years 10.19%
5Years 21.01%
7Years 36.30%
10Years 34.17%
-121 M OPERATING INCOME
-20669.42%
Growth Rates
1Year 57.50%
3Years -130.55%
5Years -42.75%
7Years -6.70%
10Years -2.74%
-131 M NET INCOME
-17292.19%
Growth Rates
1Year 56.86%
3Years -92.82%
5Years -31.14%
7Years -3.99%
10Years -1.90%
-18.3 M OPERATING CASH FLOW
-170.55%
Growth Rates
1Year 176.16%
3Years -39.86%
5Years -10.38%
7Years 13.09%
10Years 9.13%
9.19 M INVESTING CASH FLOW
83.35%
Growth Rates
1Year 72.61%
3Years 49.91%
5Years 16.24%
7Years -37.81%
10Years 4.04%
-4.69 M FINANCING CASH FLOW
-203.65%
Growth Rates
1Year 103.43%
3Years -45.59%
5Years -19.14%
7Years -17.58%
10Years 8.68%
Balance Sheet Tandem Diabetes Care, Inc.
image
Current Assets 724 M
Cash & Short-Term Investments 438 M
Receivables 115 M
Other Current Assets 172 M
Non-Current Assets 243 M
Long-Term Investments 74.5 M
PP&E 163 M
Other Non-Current Assets 5.17 M
45.30 %11.84 %17.73 %7.70 %16.89 %Total Assets$967.7m
Current Liabilities 247 M
Accounts Payable 44.7 M
Short-Term Debt 40.7 M
Other Current Liabilities 162 M
Non-Current Liabilities 458 M
Long-Term Debt 308 M
Other Non-Current Liabilities 149 M
6.35 %5.77 %22.94 %43.75 %21.18 %Total Liabilities$704.6m
EFFICIENCY
Earnings Waterfall Tandem Diabetes Care, Inc.
image
Revenue 940 M
Cost Of Revenue 451 M
Gross Profit 490 M
Operating Expenses 589 M
Operating Income -99.1 M
Other Expenses -3.1 M
Net Income -96 M
1b1b800m800m600m600m400m400m200m200m00(200m)(200m)940m(451m)490m(589m)(99m)3m(96m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
52.07% GROSS MARGIN
52.07%
Averages
1Year 52.07%
3Years 50.93%
5Years 51.71%
7Years 51.57%
10Years 46.65%
-10.54% OPERATING MARGIN
-10.54%
Averages
1Year -10.54%
3Years -16.48%
5Years -9.96%
7Years -11.24%
10Years -32.45%
-10.21% NET MARGIN
-10.21%
Averages
1Year -10.21%
3Years -17.26%
5Years -11.29%
7Years -18.57%
10Years -39.63%
-36.50% ROE
-36.50%
Averages
1Year -36.50%
3Years -42.99%
5Years -26.95%
7Years -34.41%
10Years 130.35%
-9.92% ROA
-9.92%
Averages
1Year -9.92%
3Years -14.09%
5Years -9.07%
7Years -16.05%
10Years -32.11%
-13.61% ROIC
-13.61%
Averages
1Year -13.61%
3Years -16.98%
5Years -10.21%
7Years -12.85%
10Years -36.26%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tandem Diabetes Care, Inc.
image
100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -96 M
Depreciation & Amortization 14.3 M
Capital Expenditures -19.2 M
Stock-Based Compensation 101 M
Change in Working Capital 0
Others 4.58 M
Free Cash Flow 4.99 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tandem Diabetes Care, Inc.
image
Wall Street analysts predict an average 1-year price target for TNDM of $45.2 , with forecasts ranging from a low of $22 to a high of $65 .
TNDM Lowest Price Target Wall Street Target
22 USD 50.38%
TNDM Average Price Target Wall Street Target
45.2 USD 209.30%
TNDM Highest Price Target Wall Street Target
65 USD 344.29%
Price
Max Price Target
Min Price Target
Average Price Target
7070606050504040303020201010Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Tandem Diabetes Care, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.24 M USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
191 K USD 1
3-6 MONTHS
12.4 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM) The heavy selling pressure might have exhausted for Tandem Diabetes Care (TNDM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 4 days ago
Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Dia. businesswire.com - 3 weeks ago
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech. investors.com - 3 weeks ago
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 + Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor. zacks.com - 1 month ago
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. “Diabetes management is. businesswire.com - 1 month ago
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to h. businesswire.com - 1 month ago
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue? Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Should Tandem Diabetes Stock Stay in Your Portfolio Now? Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations. zacks.com - 2 months ago
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States. zacks.com - 2 months ago
Tandem Diabetes Care, Inc. (TNDM) Q1 2025 Earnings Conference Call Transcript Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - President & CEO Leigh Vosseller - EVP & CFO Conference Call Participants Matt Miksic - Barclays Mat Blackman - Stifel Steve Lichtman - Oppenheimer & Company Matthew O'Brien - Piper Sandler David Roman - Goldman Sachs Matthew Taylor - Jeffries Chris Pasquale - Nephron Research Anthony Petrone - Mizuho Financial Groups Joshua Jennings - TD Cowen Issie Kirby - Redburn Atlantic Nathan Trebek - Wells Fargo Mike Kratky - Leerink Partners Jayson Bedford - Raymond James & Associates William Plovanic - Canaccord Genuity Michael Polark - Wolfe Research Danielle Antalffy - UBS Stephanie Piazzolla - Bank of America Securities Shagun Singh - RBC Operator Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care First Quarter 2025 Earnings Conference Call. seekingalpha.com - 2 months ago
Tandem Diabetes Care (TNDM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.63 per share a year ago. zacks.com - 2 months ago
8. Profile Summary

Tandem Diabetes Care, Inc. TNDM

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 974 M
Dividend Yield 0.00%
Description Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Contact 11075 Roselle Street, San Diego, CA, 92121 https://www.tandemdiabetes.com
IPO Date Nov. 14, 2013
Employees 2650
Officers Ms. Elizabeth Anne Gasser Executive Vice President and Chief Strategy & Product Officer Mr. John F. Sheridan President, Chief Executive Officer & Director Ms. Leigh A. Vosseller Executive Vice President, Chief Financial Officer & Treasurer Ms. Shannon M. Hansen J.D. Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary Mr. Rick A. Carpenter Chief Technical Officer Mr. Mark Novara Executive Vice President & Chief Commercial Officer Mr. Tom Fox Chief Human Resources Officer Ms. Susan M. Morrison Executive Vice President & Chief Administrative Officer Dr. Jordan Pinsker M.D. Chief Medical Officer Mr. Jean-Claude E. Kyrillos Executive Vice President & Chief Operating Officer